XML 54 R43.htm IDEA: XBRL DOCUMENT
v3.23.2

Segment Information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2023
Segment Reporting [Abstract] |
Components of Segment Revenues and Adjusted EBITDA | Segment revenues and Adjusted EBITDA consisted of the following:
|  | Three Months Ended June 30, |  |
|  | 2023 |  |  | 2022 |  |
|  |  |  |  | Segment |  |  |  |  |  | Segment |  |
|  | Segment |  |  | Adjusted |  |  | Segment |  |  | Adjusted |  |
|  | Revenues |  |  | EBITDA |  |  | Revenues |  |  | EBITDA(4) |  |
Assessment, Permitting and Response |  | $ | 61,411 |  |  | $ | 13,833 |  |  | $ | 50,037 |  |  | $ | 10,809 |  |
Measurement and Analysis |  |  | 50,055 |  | (1) |  | 10,789 |  |  |  | 42,224 |  | (1) |  | 7,047 |  | (3)
Remediation and Reuse |  |  | 47,635 |  |  |  | 6,043 |  |  |  | 47,649 |  |  |  | 7,056 |  |
Total Operating Segments |  |  | 159,101 |  |  |  | 30,665 |  |  |  | 139,910 |  |  |  | 24,912 |  |
Corporate and Other |  |  | — |  |  |  | (9,474 | ) |  |  | — |  |  |  | (8,399 | ) |
Total |  | $ | 159,101 |  |  | $ | 21,191 |  |  | $ | 139,910 |  |  | $ | 16,513 |  |
|  | Six Months Ended June 30, |  |
|  | 2023 |  |  | 2022 |  |
|  |  |  |  | Segment |  |  |  |  |  | Segment |  |
|  | Segment |  |  | Adjusted |  |  | Segment |  |  | Adjusted |  |
|  | Revenues |  |  | EBITDA |  |  | Revenues |  |  | EBITDA(4) |  |
Assessment, Permitting and Response |  | $ | 113,625 |  |  | $ | 28,099 |  |  | $ | 95,637 |  |  | $ | 20,432 |  |
Measurement and Analysis |  |  | 92,582 |  | (2) |  | 17,176 |  |  |  | 81,985 |  | (2) |  | 13,369 |  | (3)
Remediation and Reuse |  |  | 84,322 |  |  |  | 11,321 |  |  |  | 96,968 |  |  |  | 15,049 |  |
Total Operating Segments |  |  | 290,529 |  |  |  | 56,596 |  |  |  | 274,590 |  |  |  | 48,850 |  |
Corporate and Other |  |  | — |  |  |  | (18,802 | ) |  |  | — |  |  |  | (15,886 | ) |
Total |  | $ | 290,529 |  |  | $ | 37,794 |  |  | $ | 274,590 |  |  | $ | 32,964 |  |
_____________________________________ (1) Includes revenue of $2.4 million and $3.4 million from the Discontinuing Specialty Lab, for the three months ended June 30, 2023 and June 30, 2022, respectively. (2) Includes revenue of $3.9 million and $9.0 million from the Discontinuing Specialty Lab, for the six months ended June 30, 2023 and June 30, 2022, respectively. (3) Includes Adjusted EBITDA loss of $(0.9) million and Adjusted EBITDA of $0.4 million from the Discontinuing Specialty Lab for the three and six months ended June 30, 2022, respectively. (4) Includes the add back of start-up losses and investment in new services of $0.9 million and $1.7 million for the three and six months ended June 30, 2022, respectively .
Reconciliation of Segment Measure to Net Loss | Presented below is a reconciliation of the Company’s segment measure to net loss:
|  | For the Three Months Ended June 30, |  |  | For the Six Months Ended June 30, |  |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |  |
Total |  | $ | 21,191 |  |  | $ | 16,513 |  |  | $ | 37,794 |  |  | $ | 32,964 |  |
Interest expense, net |  |  | (1,877 | ) |  |  | (1,518 | ) |  |  | (3,418 | ) |  |  | (2,610 | ) |
Income tax expense |  |  | (151 | ) |  |  | (831 | ) |  |  | (1,518 | ) |  |  | (2,100 | ) |
Depreciation and amortization |  |  | (11,398 | ) |  |  | (12,280 | ) |  |  | (21,953 | ) |  |  | (24,424 | ) |
Stock-based compensation |  |  | (11,090 | ) |  |  | (10,932 | ) |  |  | (24,125 | ) |  |  | (21,357 | ) |
Start-up losses and investment in new services |  |  | — |  |  |  | (885 | ) |  |  | — |  |  |  | (1,671 | ) |
Acquisition costs |  |  | (2,696 | ) |  |  | (519 | ) |  |  | (3,471 | ) |  |  | (986 | ) |
Fair value changes in financial instruments |  |  | 865 |  |  |  | 407 |  |  |  | (1,008 | ) |  |  | 2,856 |  |
Fair value changes in business acquisition contingencies |  |  | (353 | ) |  |  | 3,510 |  |  |  | 45 |  |  |  | 3,531 |  |
Expenses related to financing transactions |  |  | — |  |  |  | — |  |  |  | (4 | ) |  |  | (7 | ) |
Discontinuing Specialty Lab |  |  | (1,583 | ) | (1) |  | — |  |  |  | (4,019 | ) | (1) |  | — |  |
Other losses or expenses |  |  | (82 | ) |  |  | (1,216 | ) | (2) |  | (216 | ) |  |  | (1,483 | ) | (2)
Net loss |  | $ | (7,174 | ) |  | $ | (7,751 | ) |  | $ | (21,893 | ) |  | $ | (15,287 | ) |
__________________________ (1) Amounts consist of operating losses before depreciation related to the Discontinuing Specialty Lab. (2) Amounts include costs associated with the closing of a lab.

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration